Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Provided By GlobeNewswire
Last update: Oct 30, 2024
Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue
Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments
Read more at globenewswire.com
